NCT03697304 is a Phase 2 clinical trial of Ezabenlimab in Neoplasm Metastasis, sponsored by Boehringer Ingelheim.

Who is sponsoring NCT03697304?

NCT03697304 is sponsored by Boehringer Ingelheim.

What drugs are being tested in NCT03697304?

Interventions in NCT03697304: Ezabenlimab, BI 754111, BI 836880.

What condition does NCT03697304 study?

NCT03697304 studies Neoplasm Metastasis, Advanced Tumors, Metastatic Solid Tumors.

Is NCT03697304 still recruiting?

NCT03697304 is currently completed. Last updated 27 January 2026.

Are results published for NCT03697304?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2026-01-27 · How we verify

NCT03697304

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours

Completed Phase 2 Results posted Last updated 27 January 2026

What this trial tests

Phase 2 trial testing Ezabenlimab in Neoplasm Metastasis in 211 participants. Completed in 3 December 2024.

Timeline

19 March 2019

Primary endpoint
3 December 2024

3 December 2024

Quick facts

Lead sponsor	Boehringer Ingelheim
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	211
Start date	19 March 2019
Primary completion	3 December 2024
Estimated completion	3 December 2024
Sites	17 locations across United Kingdom, Canada, United States

Drugs / interventions tested

Ezabenlimab — full drug profile →
BI 754111 — full drug profile →
BI 836880 — full drug profile →

Conditions studied

Neoplasm Metastasis — all drugs for Neoplasm Metastasis →
Advanced Tumors — all drugs for Advanced Tumors →
Metastatic Solid Tumors — all drugs for Metastatic Solid Tumors →

Sponsor

Boehringer Ingelheim — full company profile →

Who can join

18 and older, any sex, with Neoplasm Metastasis or Advanced Tumors. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

[Module C] Duration of Response (DoR) Secondary · From first documented CR or PR (RECIST v1.1) until the earlier of disease progression or death. Up to 174.6 weeks.

Duration of response (DoR) was defined as the time from first documented complete response (CR) or partial response (PR) (RECIST v1.1) among patients with objective response (OR), according to Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1 (v1.1). Complete response (CR) was defined as the disappearance of all target lesions and partial response (PR) was defined as decrease of at least 30% in the sum of the diameter of target lesions taking the baseline sum diameters as reference. DoR parameters were calculated based on Kaplan-Meier estimation. The analysis was performed on

Group	Value	95% CI
Module C, Cohort 1: GEC Patients	105.95	12.3 – 174.6
Module C, Cohort 2: 2ary Resistance Patients	30.90	6.4 – 81.3
Module C, Cohort 3: 1ary Resistance Patients	8.50	8.4 – 8.6
Module C, Cohort 4: CRC Patients	25.00	12.1 – 37.9
Module C, Cohort 5: EC Patients	47.30	6.1 – 143.1

[Module C] Disease Control (DC) Secondary · From first drug administration until the earliest of disease progression, death or last evaluable tumor assessment before start of subsequent anti-cancer therapy. Up to approximately 188.3 weeks.

Disease Control (DC) defined as the percentage of patients with best overall response of complete response (CR), partial response (PR), or stable disease (SD), assessed by the investigator according to Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1 (v1.1). CR was defined as the disappearance of all target lesions, PR was defined as decrease of at least 30% in the sum of the diameter of target lesions taking the baseline sum diameters as reference, SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD)

Group	Value	95% CI
Module C, Cohort 1: GEC Patients	57.1	37.2 – 75.5
Module C, Cohort 2: 2ary Resistance Patients	73.3	54.1 – 87.7
Module C, Cohort 3: 1ary Resistance Patients	42.9	24.5 – 62.8
Module C, Cohort 4: CRC Patients	56.7	37.4 – 74.5
Module C, Cohort 5: EC Patients	77.8	52.4 – 93.6

[Module C] Disease Control (DC) - Bayesian Hierarchical Model Secondary · From first drug administration until the earliest of disease progression, death or last evaluable tumor assessment before start of subsequent anti-cancer therapy. Up to approximately 188.3 weeks.

Disease Control (DC), defined as the disease control rate (DCR) of participants with best overall response of complete response (CR), partial response (PR), or stable disease (SD), assessed by the investigator according to Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1 (v1.1). CR was defined as the disappearance of all target lesions, PR was defined as decrease of at least 30% in the sum of the diameter of target lesions taking the baseline sum diameters as reference, SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for pro

Group	Value	95% CI
Module C, Cohort 1: GEC Patients	NA	NA – NA
Module C, Cohort 2: 2ary Resistance Patients	NA	NA – NA
Module C, Cohort 3: 1ary Resistance Patients	NA	NA – NA
Module C, Cohort 4: CRC Patients	NA	NA – NA
Module C, Cohort 5: EC Patients	NA	NA – NA

[Module C] Progression-free Survival (PFS) Secondary · From first drug administration until PD or death, whichever occurred earlier. Up to approximately 186.1 weeks.

Progression-free survival (PFS) was defined as the time from first treatment administration until progressive disease (PD), according to Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1 (v1.1), or death from any cause, whichever occurred earlier. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. PFS parameters were calculated based on Kaplan-Meier estimation.

Group	Value	95% CI
Module C, Cohort 1: GEC Patients	13.4	6.1 – 33.7
Module C, Cohort 2: 2ary Resistance Patients	29.1	13.0 – 48.7
Module C, Cohort 3: 1ary Resistance Patients	6.1	5.7 – 12.1
Module C, Cohort 4: CRC Patients	12.6	6.1 – 23.6
Module C, Cohort 5: EC Patients	75.0	24.9 – NA

[Module A] Duration of Response (DoR) Secondary · From first documented CR or PR (RECIST v1.1) until the earlier of disease progression or death. Up to 63.6 weeks.

Group	Value	95% CI
Module A, Cohort 2: 2ary Resistance Patients	12.30	5.7 – 31.4
Module A, Cohort 3: 1ary Resistance Patients	28.30	0.1 – 63.6

[Module A] Disease Control (DC) Secondary · From first drug administration until the earliest of disease progression, death or last evaluable tumor assessment before start of subsequent anti-cancer therapy. Up to approximately 152.4 weeks.

Group	Value	95% CI
Module A, Cohort 1: GEC Patients	0	0.0 – 84.2
Module A, Cohort 2: 2ary Resistance Patients	42.4	25.5 – 60.8
Module A, Cohort 3: 1ary Resistance Patients	45.2	29.8 – 61.3

[Module A] Disease Control (DC) - Bayesian Hierarchical Model Secondary · From first drug administration until the earliest of disease progression, death or last evaluable tumor assessment before start of subsequent anti-cancer therapy. Up to approximately 152.4 weeks.

Group	Value	95% CI
Module A, Cohort 1: GEC Patients	NA	NA – NA
Module A, Cohort 2: 2ary Resistance Patients	NA	NA – NA
Module A, Cohort 3: 1ary Resistance Patients	NA	NA – NA

[Module A] Progression-free Survival (PFS) Secondary · From first drug administration until PD, death, or cut-off date of July 2021, whichever occurred earlier. Up to approximately 104.7 weeks.

Group	Value	95% CI
Module A, Cohort 1: GEC Patients	5.9	5.7 – NA
Module A, Cohort 2: 2ary Resistance Patients	6.7	5.9 – 11.9
Module A, Cohort 3: 1ary Resistance Patients	8.9	5.7 – 16.9

[Module C] Objective Response (OR) Primary · From first drug administration until the earliest of disease progression, death or last evaluable tumor assessment before start of subsequent anti-cancer therapy. Up to approximately 188.3 weeks.

Confirmed objective response (OR), defined as the percentage of participants with best overall response of complete response (CR) or partial response (PR), assessed by the investigator according to Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1 (v1.1). Complete response (CR) was defined as the disappearance of all target lesions and partial response (PR) was defined as decrease of at least 30% in the sum of the diameter of target lesions taking the baseline sum diameters as reference.

Group	Value	95% CI
Module C, Cohort 1: GEC Patients	14.3	4.0 – 32.7
Module C, Cohort 2: 2ary Resistance Patients	23.3	9.9 – 42.3
Module C, Cohort 3: 1ary Resistance Patients	0.0	0.0 – 12.3
Module C, Cohort 4: CRC Patients	3.3	0.1 – 17.2
Module C, Cohort 5: EC Patients	44.4	21.5 – 69.2

[Module C] Objective Response (OR) - Bayesian Hierarchical Model Primary · From first drug administration until the earliest of disease progression, death or last evaluable tumor assessment before start of subsequent anti-cancer therapy. Up to approximately 188.3 weeks.

Confirmed objective response (OR), defined as the objective response rate (ORR) of participants with best overall response of complete response (CR) or partial response (PR), assessed by the investigator according to Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1 (v1.1). Complete response (CR) was defined as the disappearance of all target lesions and partial response (PR) was defined as decrease of at least 30% in the sum of the diameter of target lesions taking the baseline sum diameters as reference. The estimated objective response rate is presented by the posterior med

Group	Value	95% CI
Module C, Cohort 1: GEC Patients	NA	NA – NA
Module C, Cohort 2: 2ary Resistance Patients	NA	NA – NA
Module C, Cohort 3: 1ary Resistance Patients	NA	NA – NA
Module C, Cohort 4: CRC Patients	NA	NA – NA
Module C, Cohort 5: EC Patients	NA	NA – NA

[Module A] Objective Response (OR) Primary · From first drug administration until the earliest of disease progression, death or last evaluable tumor assessment before start of subsequent anti-cancer therapy. Up to approximately 152.4 weeks.

Group	Value	95% CI
Module A, Cohort 1: GEC Patients	0.0	0.0 – 84.2
Module A, Cohort 2: 2ary Resistance Patients	6.1	0.7 – 20.2
Module A, Cohort 3: 1ary Resistance Patients	9.5	2.7 – 22.6

[Module A] Objective Response (OR) - Bayesian Hierarchical Model Primary · From first drug administration until the earliest of disease progression, death or last evaluable tumor assessment before start of subsequent anti-cancer therapy. Up to approximately 152.4 weeks.

Group	Value	95% CI
Module A, Cohort 1: GEC Patients	NA	NA – NA
Module A, Cohort 2: 2ary Resistance Patients	NA	NA – NA
Module A, Cohort 3: 1ary Resistance Patients	NA	NA – NA

Adverse events — posted to ClinicalTrials.gov

Time frame: Adverse event reporting and all-cause mortality: From first until last drug administration plus residual effect period (30 days). Up to approximately 192.6 weeks for module C and approximately 156.7 weeks for module A.. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Module C, Cohort 1: GEC Patients

Serious: 11/28 (39%)

Deaths: 24/28

Module C, Cohort 2: 2ary Resistance Patients

Serious: 18/30 (60%)

Deaths: 20/30

Module C, Cohort 3: 1ary Resistance Patients

Serious: 12/28 (43%)

Deaths: 22/28

Module C, Cohort 4: CRC Patients

Serious: 13/30 (43%)

Deaths: 17/30

Module C, Cohort 5: EC Patients

Serious: 11/18 (61%)

Deaths: 4/18

Module A, Cohort 1: GEC Patients

Serious: 1/2 (50%)

Deaths: 0/2

Module A, Cohort 2: 2ary Resistance Patients

Serious: 13/33 (39%)

Deaths: 29/33

Module A, Cohort 3: 1ary Resistance Patients

Serious: 12/42 (29%)

Deaths: 32/42

Serious adverse events (105 terms)

Reaction	System	Module C, Cohort 1: GEC Pa…	Module C, Cohort 2: 2ary R…	Module C, Cohort 3: 1ary R…	Module C, Cohort 4: CRC Pa…	Module C, Cohort 5: EC Pat…	Module A, Cohort 1: GEC Pa…	Module A, Cohort 2: 2ary R…	Module A, Cohort 3: 1ary R…
DEEP VEIN THROMBOSIS	VASCULAR DISORDERS	—	—	—	—	—	—	—	—
ASCITES	GASTROINTESTINAL DISORDERS	—	—	—	—	—	—	—	—
OESOPHAGEAL PERFORATION	GASTROINTESTINAL DISORDERS	—	—	—	—	—	—	—	—
SMALL INTESTINAL OBSTRUCTION	GASTROINTESTINAL DISORDERS	—	—	—	—	—	—	—	—
PAIN	GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	—	—	—	—	—	—	—	—
PNEUMONIA ASPIRATION	INFECTIONS AND INFESTATIONS	—	—	—	—	—	—	—	—
URINARY TRACT INFECTION	INFECTIONS AND INFESTATIONS	—	—	—	—	—	—	—	—
FALL	INJURY, POISONING AND PROCEDURAL COMPLICATIONS	—	—	—	—	—	—	—	—
ASPIRATION	RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	—	—	—	—	—	—	—	—
PLEURAL EFFUSION	RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	—	—	—	—	—	—	—	—
PNEUMOTHORAX	RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	—	—	—	—	—	—	—	—
HYPERTENSION	VASCULAR DISORDERS	—	—	—	—	—	—	—	—
ANAEMIA	BLOOD AND LYMPHATIC SYSTEM DISORDERS	—	—	—	—	—	—	—	—
BANDAEMIA	BLOOD AND LYMPHATIC SYSTEM DISORDERS	—	—	—	—	—	—	—	—
IMMUNE THROMBOCYTOPENIA	BLOOD AND LYMPHATIC SYSTEM DISORDERS	—	—	—	—	—	—	—	—
NEUTROPENIA	BLOOD AND LYMPHATIC SYSTEM DISORDERS	—	—	—	—	—	—	—	—
ACUTE LEFT VENTRICULAR FAILURE	CARDIAC DISORDERS	—	—	—	—	—	—	—	—
ACUTE MYOCARDIAL INFARCTION	CARDIAC DISORDERS	—	—	—	—	—	—	—	—
ATRIAL FIBRILLATION	CARDIAC DISORDERS	—	—	—	—	—	—	—	—
ATRIOVENTRICULAR BLOCK COMPLETE	CARDIAC DISORDERS	—	—	—	—	—	—	—	—
CARDIAC ARREST	CARDIAC DISORDERS	—	—	—	—	—	—	—	—
MYOCARDITIS	CARDIAC DISORDERS	—	—	—	—	—	—	—	—
PERICARDIAL EFFUSION	CARDIAC DISORDERS	—	—	—	—	—	—	—	—
SUPRAVENTRICULAR TACHYCARDIA	CARDIAC DISORDERS	—	—	—	—	—	—	—	—
ADRENAL INSUFFICIENCY	ENDOCRINE DISORDERS	—	—	—	—	—	—	—	—

Other adverse events (153 terms — click to expand)

Reaction	System	Module C, Cohort 1: GEC Pa…	Module C, Cohort 2: 2ary R…	Module C, Cohort 3: 1ary R…	Module C, Cohort 4: CRC Pa…	Module C, Cohort 5: EC Pat…	Module A, Cohort 1: GEC Pa…	Module A, Cohort 2: 2ary R…	Module A, Cohort 3: 1ary R…
FATIGUE	GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	—	—	—	—	—	—	—	—
WEIGHT DECREASED	INVESTIGATIONS	—	—	—	—	—	—	—	—
NAUSEA	GASTROINTESTINAL DISORDERS	—	—	—	—	—	—	—	—
OEDEMA PERIPHERAL	GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	—	—	—	—	—	—	—	—
CONSTIPATION	GASTROINTESTINAL DISORDERS	—	—	—	—	—	—	—	—
VOMITING	GASTROINTESTINAL DISORDERS	—	—	—	—	—	—	—	—
COUGH	RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	—	—	—	—	—	—	—	—
DIARRHOEA	GASTROINTESTINAL DISORDERS	—	—	—	—	—	—	—	—
DECREASED APPETITE	METABOLISM AND NUTRITION DISORDERS	—	—	—	—	—	—	—	—
HYPERTENSION	VASCULAR DISORDERS	—	—	—	—	—	—	—	—
ABDOMINAL PAIN	GASTROINTESTINAL DISORDERS	—	—	—	—	—	—	—	—
ARTHRALGIA	MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS	—	—	—	—	—	—	—	—
HYPOTHYROIDISM	ENDOCRINE DISORDERS	—	—	—	—	—	—	—	—
DEHYDRATION	METABOLISM AND NUTRITION DISORDERS	—	—	—	—	—	—	—	—
ANAEMIA	BLOOD AND LYMPHATIC SYSTEM DISORDERS	—	—	—	—	—	—	—	—
URINARY TRACT INFECTION	INFECTIONS AND INFESTATIONS	—	—	—	—	—	—	—	—
BLOOD CREATININE INCREASED	INVESTIGATIONS	—	—	—	—	—	—	—	—
BACK PAIN	MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS	—	—	—	—	—	—	—	—
DIZZINESS	NERVOUS SYSTEM DISORDERS	—	—	—	—	—	—	—	—
HEADACHE	NERVOUS SYSTEM DISORDERS	—	—	—	—	—	—	—	—
DYSPNOEA	RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	—	—	—	—	—	—	—	—
HYPOTENSION	VASCULAR DISORDERS	—	—	—	—	—	—	—	—
PYREXIA	GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	—	—	—	—	—	—	—	—
UPPER RESPIRATORY TRACT INFECTION	INFECTIONS AND INFESTATIONS	—	—	—	—	—	—	—	—
BLOOD ALKALINE PHOSPHATASE INCREASED	INVESTIGATIONS	—	—	—	—	—	—	—	—
HYPOKALAEMIA	METABOLISM AND NUTRITION DISORDERS	—	—	—	—	—	—	—	—
PROTEINURIA	RENAL AND URINARY DISORDERS	—	—	—	—	—	—	—	—
PRURITUS	SKIN AND SUBCUTANEOUS TISSUE DISORDERS	—	—	—	—	—	—	—	—
CHILLS	GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	—	—	—	—	—	—	—	—
COVID-19	INFECTIONS AND INFESTATIONS	—	—	—	—	—	—	—	—
PNEUMONIA	INFECTIONS AND INFESTATIONS	—	—	—	—	—	—	—	—
INFUSION RELATED REACTION	INJURY, POISONING AND PROCEDURAL COMPLICATIONS	—	—	—	—	—	—	—	—
ASPARTATE AMINOTRANSFERASE INCREASED	INVESTIGATIONS	—	—	—	—	—	—	—	—
PLATELET COUNT DECREASED	INVESTIGATIONS	—	—	—	—	—	—	—	—
HYPERCALCAEMIA	METABOLISM AND NUTRITION DISORDERS	—	—	—	—	—	—	—	—
HYPERURICAEMIA	METABOLISM AND NUTRITION DISORDERS	—	—	—	—	—	—	—	—
FLANK PAIN	MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS	—	—	—	—	—	—	—	—
MUSCLE SPASMS	MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS	—	—	—	—	—	—	—	—
NECK PAIN	MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS	—	—	—	—	—	—	—	—
PAIN IN EXTREMITY	MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS	—	—	—	—	—	—	—	—

Most-reported serious reactions: DEEP VEIN THROMBOSIS, ASCITES, OESOPHAGEAL PERFORATION, SMALL INTESTINAL OBSTRUCTION, PAIN, PNEUMONIA ASPIRATION, URINARY TRACT INFECTION, FALL.

Data from ClinicalTrials.gov NCT03697304 adverse events section.

Sponsor's own description

This is a study in adults with various types of advanced cancer. The purpose of the study is to test a medicine called BI 754091 in combination with several other cancer medicines. BI 754091 is an immunotherapy. This means it may help the immune system fight cancer. Such therapies are also called immune checkpoint inhibitors. How long the participants are in the study depends on whether they benefit from treatment and whether they experience unacceptable side effects. The participants are put into different groups. Each group receives BI 754091 in combination with another medicine. The doctors check whether the tumors shrink or disappear. The doctors also check the general health of the participants.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4.
Qin S, Xu L, Yi M, Yu S, et al · · 2019 · cited 909× · PMID 31690319 · DOI 10.1186/s12943-019-1091-2
Next generation of immune checkpoint inhibitors and beyond.
Marin-Acevedo JA, Kimbrough EO, Lou Y. · · 2021 · cited 401× · PMID 33741032 · DOI 10.1186/s13045-021-01056-8
Emerging new therapeutic antibody derivatives for cancer treatment.
Jin S, Sun Y, Liang X, Gu X, et al · · 2022 · cited 304× · PMID 35132063 · DOI 10.1038/s41392-021-00868-x
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts.
Wang Y, Zhang H, Liu C, Wang Z, et al · · 2022 · cited 179× · PMID 35978433 · DOI 10.1186/s13045-022-01325-0
Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy.
Cao Y, Wang X, Jin T, Tian Y, et al · · 2020 · cited 133× · PMID 33122640 · DOI 10.1038/s41392-020-00348-8
A comprehensive comparison between camelid nanobodies and single chain variable fragments.
Asaadi Y, Jouneghani FF, Janani S, Rahbarizadeh F. · · 2021 · cited 123× · PMID 34863296 · DOI 10.1186/s40364-021-00332-6
Future Therapeutic Directions for Smac-Mimetics.
Morrish E, Brumatti G, Silke J. · · 2020 · cited 108× · PMID 32053868 · DOI 10.3390/cells9020406
Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target.
Qian W, Zhao M, Wang R, Li H. · · 2021 · cited 96× · PMID 34526102 · DOI 10.1186/s13045-021-01161-8

Verify or expand the search:

Other trials of Ezabenlimab

Trials testing the same drug.

NCT07395258 — A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Differe · Phase 1 · recruiting
NCT06370871 — Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Ti · Phase 3 · withdrawn
NCT06091930 — A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Can · Phase 1 · active not recruiting
NCT05879978 — A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by Peop · Phase 1 · active not recruiting
NCT05846516 — A Study to Test KISIMA-02 Vaccine-based Immunotherapy and Ezabenlimab in People With Pancreatic Cancer · Phase 1 · active not recruiting

Other recruiting trials for Neoplasm Metastasis

Currently open trials in the same condition.

NCT06912087 — Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC · Phase 1 · recruiting
NCT06534580 — Virtual Reality for Advanced Cancer Pain · active not recruiting
NCT06460961 — A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-68 · Phase 1 · active not recruiting
NCT05573893 — PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Dat · recruiting
NCT06046131 — Clinical, Genetic and Environmental Determinants of Prostate Cancer Progression. · NA · recruiting

Other Boehringer Ingelheim trials

Trials by the same sponsor.

NCT07044700 — Real-world Comparative Effectiveness and Safety of Jardiance in Chinese Patients With Heart Failure of Reduced Ejection · not yet recruiting
NCT07047508 — Real-world Study to Describe the Effectiveness and Safety Outcomes of Jardiance in Chinese Patients With Heart Failure a · not yet recruiting
NCT07366034 — A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With I · Phase 3 · not yet recruiting
NCT07531628 — A Study to Test How Verducatib is Taken up in the Body of Healthy Chinese Participants · Phase 1 · not yet recruiting
NCT07497087 — A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03697304 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Boehringer Ingelheim
Last refreshed: 27 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03697304.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing